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Tests for disease often produce a continuous measure, such as the concentra-
tion of some biomarker in a blood sample. In clinical practice, a threshold C
is selected such that results, say, greater than C are declared positive and those
less than C negative. Measures of test accuracy such as sensitivity and speci-
ficity depend crucially on C, and the optimal value of this threshold is usually
a key question for clinical practice. Standard methods for meta-analysis of test
accuracy (i) do not provide summary estimates of accuracy at each threshold,
precluding selection of the optimal threshold, and furthermore, (ii) do not make
use of all available data. We describe a multinomial meta-analysis model that
can take any number of pairs of sensitivity and specificity from each study
and explicitly quantifies how accuracy depends on C. Our model assumes that
some prespecified or Box-Cox transformation of test results in the diseased and
disease-free populations has a logistic distribution. The Box-Cox transformation
parameter can be estimated from the data, allowing for a flexible range of under-
lying distributions.We parameterise in terms of themeans and scale parameters
of the two logistic distributions. In addition to credible intervals for the pooled
sensitivity and specificity across all thresholds, we produce prediction intervals,
allowing for between-study heterogeneity in all parameters.We demonstrate the
model using two case study meta-analyses, examining the accuracy of tests for
acute heart failure and preeclampsia. We show how the model can be extended
to explore reasons for heterogeneity using study-level covariates.
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1 INTRODUCTION
Many diagnostic tests produce an explicit continuous measure, which is dichotomised at some threshold to call the result
positive or negative. Identifying the optimal threshold to be used in practice is usually of key clinical importance. In
addressing this question, standard methods for meta-analysis of test accuracy1-3 have two major shortcomings. Firstly,
these methods produce only a “summary” estimate of sensitivity and specificity and/or a summary receiver operat-
ing characteristic (ROC) curve: they do not explicitly quantify test accuracy at each possible threshold. Secondly, they
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synthesise only a single estimate of sensitivity and specificity from each study, despite studies very often reporting
estimates at multiple thresholds.4 The presence of these additional data is widely regarded as problematic, due to the
additional complexities in data synthesis. However, within-study information on how test accuracy varies with threshold
could clearly be extremely valuable, both for quantifying the average sensitivity and specificity across all thresholds and
for disentangling heterogeneity due to varying thresholds from that due to other factors.
A simple approach to addressing both problems is to perform a separate meta-analysis of the data at each threshold
or for groups of similar thresholds. The Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy notes
that “Each study can contribute to one or more analyses depending on what thresholds it reports”.5 This will produce
summary estimates of the sensitivity and specificity of the test at each threshold in the data set. However, case studies have
demonstrated bias in these estimates if some studies only report accuracymeasures at data-driven “optimal” thresholds.6-8
Confidence or credible intervalswill also be verywide for thresholdswith limited data. Itmight be possible to address these
problems through imputation of missing data in each study prior tometa-analysis,7,8 although accounting for uncertainty
in these imputations requires extra steps.8 An additional problem also remains: if higher values increase the likelihood
of a disease, by definition, sensitivity must reduce and specificity increase with increasing threshold. However, these
relationships will not necessarily hold in the summary estimates.
The alternative is a single unified analysis of all available data. This will enable “borrowing of strength” across thresh-
olds and produce estimates that conform to the known relationship between threshold, sensitivity, and specificity. Various
models have been proposed for such a unified analysis. Some of these produce a summary ROC curve but not estimates
of sensitivity and specificity relating to specific thresholds.9-11 Others were devised for synthesis of ordinal test results
with a small number of categories.12-14 Extensions of these models for truly continuous test results would require very
large numbers of parameters to be estimated. For example, Riley et al proposed a 2*K dimensional multivariate normal
model, where K is the total number of distinct thresholds included in the meta-analysis, but noted that this will often not
be estimable.15
An alternative approach is to explicitly model sensitivity and specificity as functions of threshold.4,15 However, there
is a lack of clarity on which function of threshold is the most appropriate. Steinhauser et al4 and Hoyer et al16 proposed
unifiedmodels that assume that test results in the diseased and disease-free populations have a prespecified distributional
form, for example, log-normal. A criticism is that the appropriate choice of distribution might not be known in advance,
however.8 Hoyer et al note that it would be a “definite advantage” if the distributions could be “estimated simultaneously
together with the other model parameters”.16
We present a new model that, compared with previous approaches, has most in common with but potential advan-
tages over that suggested by Steinhauser et al.4 We model the exact multinomial likelihoods of the spread of test results
across categories defined by thresholds, rather than requiring the normal approximations used by Steinhauser et al.4 This
approach automatically accounts for within-study correlations resulting from studies reporting at more than one thresh-
old and should perform better with small counts.2 We also relax the assumption that the appropriate distributional form
is known, assuming only that some Box-Cox transformation of test results in the two populations has a logistic distri-
bution. The Box-Cox transformation parameter can be estimated from the data. Our model is parameterised directly in
terms of the means and scale parameters of these two logistic distributions, and is easily extended to allow for study-level
covariates impacting upon any of these four parameters.
We first describe the model in Section 2, including the extended version to include study-level covariates. In Section 3,
we describe two case study data sets, to which we then apply the model in Section 4, before concluding in Section 5.
2 A GENERAL FLEXIBLE MODEL STRUCTURE
We describe a flexible model that is straightforward to fit in a Bayesian framework using Markov chain Monte Carlo
(MCMC) simulation software, such as WinBUGS17 or OpenBUGS.
2.1 Notation and within-study model
We consider the case where each study, i, reports estimates of sensitivity and specificity at Ti distinct thresholds; or,
equivalently, directly reports count data in a form such as Table 1. Ti might be equal to one in some studies, ie, it is not
required that all studies contributemore than one pair of data points.Wewill assume throughout that the true disease state
is known for all individuals, through application of some gold standard test. We denote the total number of individuals
without and with the disease in study i by Ni1 and Ni2, respectively.
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TABLE 1 Test accuracy data from a study, indexed i, providing estimates of sensitivity and specificity at Ti distinct
thresholds (Ci1,… ,CiTi )
Population Total number of patients Number with test result > Ci1 · · · Number with test result > CiTi
Disease-free Ni1 xi11 · · · xi1Ti
Diseased Ni2 xi21 · · · xi2Ti
We assume that higher values of the continuous test result are associated with increased likelihood of disease, such that
a “positive” test result is one that falls above a given threshold. At each threshold Cit, t = 1,… ,Ti, we denote the number
of false positive and true positive individuals by xi1t and xi2t, respectively (Table 1). These counts must, by definition, be
monotonically decreasing with t, a property which the model should reflect.
In each study, we can subdivide each patient population (Ni1 andNi2) into (Ti + 1) mutually exclusive groups, with test
results falling below Ci1, between Cit and Ci,t + 1 (t = 1,… ,Ti-1), and above Ci,Ti . The distribution of each of the two sets of
results across these groups is multinomial. Conditional on the underlying probability parameters, the two multinomial
distributions for each study i are independent of each other.
For model fitting purposes, it is convenient to use the binomial factorisation of these multinomial distributions,18
in which they are written as a series of conditionally independent binomial distributions, ie, for population j = 1
(disease-free) and j = 2 (diseased):
xij1 ∼ Binomial
(
Nij, prij1
)
xijt ∣ xij,t−1 ∼ Binomial
(
xij,t−1,
prijt
prij,t−1
)
, t = 2, … ,Ti,
where pri1t and pri2t are the false positive rate ( fpr) (= 1- specificity) and true positive rate (tpr) (= sensitivity) at threshold
Cit in study i. By definition, pri1t and pri2tmonotonically decreasewith increasing t and lie in [0,1], such that each Binomial
probability parameter is unconstrained within the interval [0,1]. This parameterisation obviates the need to reexpress the
Table 1 data as numbers of patients falling between each threshold value, and allows the same model code to be applied
to studies with binomial (Ti = 1) and multinomial (Ti > 1) likelihoods.
We wish to specify the tprs and fprs as functions of threshold. The appropriate function depends on the distribution
of continuous test results in the disease-free and diseased populations. We will assume that there exists some monotonic
transformation, g(), that transforms test results in each of the two populations to either a normal or logistic distribution.
This is the most common assumption made in the fitting of a smooth line to an empirical ROC curve.19 We will work on
the basis of logistic distributions throughout, which are similar to normal andmore computationally convenient (leading
to logit rather than probit link functions). We assume for now that the same g() applies to both distributions and to all
studies in the meta-analysis, but will discuss relaxing this assumption later (Section 5).
Let us denote the continuous test results of disease-free and diseased individuals in the ith study by yi1k and yi2k
respectively, where k is an index for individual. We assume that
g
(
𝑦ijk
)
∼ Logistic
(
𝜇ij, 𝜎ij
)
, 𝑗 = 1, 2,
where 𝜇ij and 𝜎ij denote mean and scale parameters for disease status group j. As g() is monotonic, prijt ≡
Pr(yijk ≥ Cit)= Pr (g(yijk)≥ g(Cit)). It follows from the cumulative distribution function of the logistic distribution that the
fprs and tprs at a threshold of Cit in study i are defined as follows:
logit
(
prijt
)
=
𝜇ij − g (Cit)
𝜎ij
, t = 1, … ,Ti ; j = 1, 2. (1)
2.2 Choice of transformation function, g()
We see from Equation (1) that to explicitly model the dependence of prijt on Cit, we need to move beyond the “semipara-
metric” or “distribution-free” approach often used to fit smooth ROC curves,19 in which the transformation function g()
remains unspecified. A fully parametric model is required. In particular, specifying logit (pri1t) and logit (pri2t) as linear
functions of untransformedCit (eg, the work of Riley et al15) would implicitly assume that g() is the identity function, that
is, that the test results in the diseased and disease-free populations have symmetric, logistic distributions.
We might be comfortable to prespecify an appropriate transformation, g(). This could be informed by inspection of the
distributions of test results from a laboratory or from one or more study publications. Often in practice, assuming g() is
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the natural logarithm (subsequently referred to simply as “log()”) will be a reasonable approximation for positive valued
test results, which are often right skewed.20 This corresponds to assuming a log-logistic distribution for each set of test
results, one of the distributional forms considered by both Steinhauser et al4 and Hoyer et al.16
If, however, the analyst is not confident about the most appropriate transformation or would like to assess sensitivity of
results to this assumption, we propose using amore flexible approach.We assume only that g() is one of the set of Box-Cox
transformations, defined by
g (Cit) =
{(
C𝜆it − 1
)
∕𝜆, if 𝜆 ≠ 0 and
log (Cit) , if 𝜆 = 0.
This reduces to the assumption of logistic distributions of underlying test results when 𝜆 = 1. As 𝜆 decreases from 1,
this indicates an increasing degree of right skew of the underlying distributions, with 𝜆 = 0 corresponding to log-logistic
distributions.
The transformation parameter 𝜆 can be estimated with uncertainty from the data. This approach was proposed by Zou
and Hall21 for the estimation of ROC curves in a single study but to our knowledge has not been previously applied in a
meta-analysis setting.
2.3 Between-study model
We assume that, across studies, 𝜇ij is normally distributed with mean m𝜇j and variance 𝜏2𝜇𝑗 , for each population j = 1,2.
Similarly, log(𝜎ij) is assumed to be normally distributed with meanm𝜎j and variance 𝜏2𝜎𝑗 .
Wewould generally anticipate some correlations across these four sets of randomeffects. Any between-study correlation
structure might be specified. Here, we describe three, each of which we will apply to our case study data sets in Section 4.
(i) Full correlation matrix
To allow for all possible between-study correlations, we can fit a full quadrivariate normal distributionwith six different
correlation parameters:
⎛⎜⎜⎜⎝
𝜇i1
𝜇i2
log (𝜎i1)
log (𝜎i2)
⎞⎟⎟⎟⎠ ∼ MVN
⎛⎜⎜⎜⎜⎝
⎛⎜⎜⎜⎝
m𝜇1
m𝜇2
m𝜎1
m𝜎2
⎞⎟⎟⎟⎠ ,
⎛⎜⎜⎜⎜⎝
𝜏2
𝜇1 𝜌𝜇𝜏𝜇1𝜏𝜇2 𝜌𝜇1𝜎1𝜏𝜇1𝜏𝜎1 𝜌𝜇1𝜎2𝜏𝜇1𝜏𝜎2
𝜌𝜇𝜏𝜇1𝜏𝜇2 𝜏
2
𝜇2 𝜌𝜇2𝜎1𝜏𝜇2𝜏𝜎1 𝜌𝜇2𝜎2𝜏𝜇2𝜏𝜎2
𝜌𝜇1𝜎1𝜏𝜇1𝜏𝜎1 𝜌𝜇2𝜎1𝜏𝜇2𝜏𝜎1 𝜏
2
𝜎1 𝜌𝜎𝜏𝜎1𝜏𝜎2
𝜌𝜇1𝜎2𝜏𝜇1𝜏𝜎2 𝜌𝜇2𝜎2𝜏𝜇2𝜏𝜎2 𝜌𝜎𝜏𝜎1𝜏𝜎2 𝜏
2
𝜎2
⎞⎟⎟⎟⎟⎠
⎞⎟⎟⎟⎟⎠
. (2)
In WinBUGS, this can be fitted using a product normal formulation, which we describe in Appendix.
(ii) Structured correlation matrix
As correlation parameters in multivariate meta-analysis models can be difficult to estimate, it is desirable to reduce the
number of these to be estimated by prespecifying a realistic correlation structure.
One simplifying set of assumptions might be that all correlations arise through dependencies between the following
three pairs of parameters: 𝜇i1 and 𝜇i2; 𝜇i1 and log(𝜎i1); 𝜇i2 and log(𝜎i2). In general, we might expect 𝜇i1 and 𝜇i2 to be posi-
tively correlated across studies. For example, study-level factors might raise or lower the expected test result in both the
diseased and disease-free populations. We will denote this correlation by 𝜌𝜇 (as in (2)). Study-specific log-scale param-
eters might also be expected to be positively correlated with means in the same patient group. We will assume that
this correlation is the same in the diseased and disease-free populations and will denote it by 𝜌𝜇𝜎 . We hypothesise that
any other correlations between random effects (for example, between 𝜇i1 and log(𝜎i2)) are likely to be induced through
𝜌𝜇 and 𝜌𝜇𝜎 .
The corresponding quadrivariate normal distribution can be written as four conditionally independent univariate
distributions as follows:
𝜇i1 ∼ Normal
(
m𝜇1, 𝜏2𝜇1
)
𝜇i2 ∣ 𝜇i1 ∼ Normal
(
m𝜇2 + 𝜌𝜇
𝜏𝜇2
𝜏𝜇1
(
𝜇i1 −m𝜇1
)
,
(
1 − 𝜌2𝜇
)
𝜏2
𝜇2
)
log
(
𝜎ij
)
∣ 𝜇ij ∼ Normal
(
m𝜎𝑗 + 𝜌𝜇𝜎
𝜏𝜎𝑗
𝜏𝜇𝑗
(
𝜇ij −m𝜇𝑗
)
,
(
1 − 𝜌2𝜇𝜎
)
𝜏2𝜎𝑗
)
, 𝑗 = 1, 2.
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(iii) Independence
For completeness, we include a model with four independent sets of random effects, ie, with all six correlation
parameters in (2) equal to 0:
𝜇ij ∼ N
(
m𝜇𝑗 , 𝜏2𝜇𝑗
)
, and
log
(
𝜎ij
)
∼ N
(
m𝜎𝑗 , 𝜏2𝜎𝑗
)
for 𝑗 = 1, 2.
2.4 Inclusion of study-level covariates
As in any meta-analysis, potential reasons for heterogeneity across studies in diagnostic test accuracy should be explored
where possible, rather than simply accommodated using random effects. It is straightforward to extend our model to
include study-level covariates, acting on either the location 𝜇ij and/or log-scale log(𝜎ij) parameters. Furthermore, while
it can be difficult to hypothesise how sensitivity and specificity might vary according to study characteristics, it seems
natural to consider how the “average” test result or the spread of test results in either population might be affected.
A generalised version of the “full” model (Equation (2)) is as follows, where zir are vectors of study-level covariates and
𝛂r are vectors of meta-regression coefficients to be estimated, r = 1,… ,4:
⎛⎜⎜⎜⎝
𝜇i1
𝜇i2
log (𝜎i1)
log (𝜎i2)
⎞⎟⎟⎟⎠ ∼ MVN
⎛⎜⎜⎜⎜⎝
⎛⎜⎜⎜⎝
m𝜇1 + 𝛂𝟏 ′zi1
m𝜇2 + 𝛂𝟐 ′zi𝟐
m𝜎1 + 𝛂𝟑 ′zi𝟑
m𝜎2 + 𝛂𝟒 ′zi𝟒
⎞⎟⎟⎟⎠ ,
⎛⎜⎜⎜⎜⎝
𝜏2
𝜇1 𝜌𝜇𝜏𝜇1𝜏𝜇2 𝜌𝜇1𝜎1𝜏𝜇1𝜏𝜎1 𝜌𝜇1𝜎2𝜏𝜇1𝜏𝜎2
𝜌𝜇𝜏𝜇1𝜏𝜇2 𝜏
2
𝜇2 𝜌𝜇2𝜎1𝜏𝜇2𝜏𝜎1 𝜌𝜇2𝜎2𝜏𝜇2𝜏𝜎2
𝜌𝜇1𝜎1𝜏𝜇1𝜏𝜎1 𝜌𝜇2𝜎1𝜏𝜇2𝜏𝜎1 𝜏
2
𝜎1 𝜌𝜎𝜏𝜎1𝜏𝜎2
𝜌𝜇1𝜎2𝜏𝜇1𝜏𝜎2 𝜌𝜇2𝜎2𝜏𝜇2𝜏𝜎2 𝜌𝜎𝜏𝜎1𝜏𝜎2 𝜏
2
𝜎2
⎞⎟⎟⎟⎟⎠
⎞⎟⎟⎟⎟⎠
. (3)
Special cases include zir = zi, r = 1,… ,4, whereby the same set of study-level covariates is hypothesised to be associated
with all four sets of random effects, and zir = 0 for some r, whereby we hypothesise associations of covariates with only a
subset of the random effects.
3 CASE STUDY DATA SETS
We now describe two case study data sets, before fitting our model to each of these in Section 4.
Example 1: Brain natriuretic peptide (BNP) for diagnosis of acute heart failure
Roberts et al22 performed a systematic review of the accuracy of brain natriuretic peptide (BNP) in diagnosing acute
heart failure in adults presenting in an acute care setting with dyspnoea. The authors extracted measures of the accuracy
of BNP, relative to a reference standard of retrospective review or final hospital diagnosis, from 26 studies of consecutive
or randomly selected patients.22 Many of these studies reported sensitivity and specificity at more than one threshold.
By checking each of the original study publications, we found that additional data were often available. In some studies,
these were not displayed in tables but were, however, shown on ROC plots, on which the thresholds corresponding to
particular points on the curve had been marked. We extracted sensitivity and specificity estimates from these plots using
the DigitizeIt software (http://www.digitizeit.de/).
It is recognised that a given BNP measurement on one assay might not translate directly to the same value on other
assays.23 For this reason, we restrict our analyses to the 18 studies that assessed the accuracy of the Triage assay (Biosite
Inc, San Diego). In total, the final data set consisted of 66 pairs of sensitivity and specificity from these 18 studies, ranging
from a single pair (four studies) to seven (three studies). The data are displayed in two formats in Figure 1: on the ROC
plane on the left, whereas on the right, we display how the probability of a positive test result for each of the two groups
of patients depends on the threshold used. The data are available from figshare.
As noted above, a common approach to synthesising data with multiple thresholds, applied by authors including
Roberts et al,22 is to group the data into categories with similar thresholds and perform a number of stratified analyses.
To demonstrate this approach, we rounded all thresholds to the nearest 50 and performed stratified analyses: for each
threshold with at least four contributing studies, we fitted the standard bivariate meta-analysis model1,2 in WinBUGS.17
Summary results are shown on Figure 1. We see that these stratified analyses produce estimates of the tpr and fpr that do
not reduce monotonically with increasing threshold. This problem is masked in the ROC plot (Figure 1, top panel) but
clearly visible when we plot summary estimates against explicit threshold values (bottom panel). Furthermore, credible
intervals are very wide and it is not possible to estimate the accuracy of BNP across all threshold values.
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FIGURE 1 Observed data on the
accuracy of Brain Natriuretic Peptide
(Triage assay only) in diagnosing acute
heart failure across the full observed range
of thresholds. Points from the same study
are joined. tpr = true positive rate
(sensitivity), fpr = false positive rate
(1-specificity). Also shown are point
estimates with 95% credible intervals from a
series of stratified bivariate meta-analyses,
in which similar thresholds are grouped
and analysed together [Colour figure can be
viewed at wileyonlinelibrary.com]
There are several potential factors thatmight influence the accuracy of BNP as a test for acute heart failure. For example,
Rogers et al24 found age, gender, ethnicity, body mass index, blood urine nitrogen, and creatinine to all be associated with
BNP levels independently of heart failure. We extracted the average age of patients in each study to explore whether the
accuracy of the test varied by this factor (values available in the figshare file).
Example 2: Spot protein to creatinine ratio (PCR) for diagnosis of preeclampsia
Morris et al25 systematically reviewed the literature for studies assessing the diagnostic accuracy of spot urinary protein
to creatinine ratio (PCR) in detecting significant proteinuria in pregnant womenwith suspected preeclampsia. Significant
proteinuria is defined as ≥0.3 g/24 hours, the “gold standard” test for which is a 24-hour urine collection. Data were
extracted from 13 studies, each of which reported sensitivity and specificity estimates at between one (five studies) and
nine (one study) thresholds.25 The data are displayed in Figure 2 and are available in full from Morris et al.25
Riley et al15 previously analysed this data set using a multivariate normal meta-regression approach, in which logit
(sensitivity) and logit (specificity) weremodelled as polynomial functions of threshold,C. They found a cubic relationship
with threshold to fit the data best. We show the summary estimates from their analysis on Figure 2 (point estimates and
95% CIs extracted from table 4 of Riley et al15). We see that the implied summary ROC curve is not concave and does not
seem to fully capture the relationship between the tprs and fprs and threshold.
4 APPLICATION TO CASE STUDY DATA SETS
We now fit our proposedmodel to each of the two case study data sets usingWinBUGS.17 We begin by fitting models with
no study-level covariates, then also explore whether heterogeneity can be explained by average patient age in the BNP
data set.We gave Normal (0,102) prior distributions to all means (m𝜇j,m𝜎j) andmeta-regression coefficients, Uniform (0,5)
distributions to between-study standard deviations (𝜏𝜇j,𝜏𝜎j), and Uniform(−1,1) prior distributions to any between-study
correlation parameters. We will compare results frommodels in which g() is prespecified with models in which the trans-
formation function 𝜆 is estimated from the data (Section 2.2). For the latter, we assigned a Uniform(−3, 3) prior to 𝜆.
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FIGURE 2 Observed data on the
accuracy of spot urinary protein to
creatinine ratio in detecting significant
proteinuria in suspected preeclampsia.
Points from the same study are joined.
tpr = true positive rate (sensitivity),
fpr = false positive rate (1-specificity). Also
shown are summary point estimates with
95% confidence intervals from an analysis
by Riley et al15 [Colour figure can be
viewed at wileyonlinelibrary.com]
TABLE 2 Comparison of model fit to the Brain natriuretic peptide data, according to the Deviance Information Criteria (DIC). D=mean
residual deviance, pD = effective number of parameters, DIC =D+ pD
Model Correlation structure Transformation, g() Study level covariates D pD DIC
1 Full correlation matrix log() None 216.7 41.0 257.7
2 Structured correlation matrix log() None 215.0 40.8 255.8
3 Independence log() None 214.1 42.5 256.6
4 Independence Box-Cox with unknown 𝜆 None 211.3 43.6 254.9
5 Independence log() 𝜇i1 and 𝜇i2 regressed on average patient age 214.7 42.9 257.6
We also performed sensitivity analyses with a Uniform(1,10) prior distribution for 𝜆, as used previously in analyses by
O'Malley and Zou.26 WinBUGS code is available from figshare.
Example 1: B-type natriuretic peptide for diagnosis of acute heart failure
Asmany of the articles in this systematic review noted that BNP values are right skewed and used the natural logarithm
of BNP values in their own analyses, eg, Karmpaliotis et al,27 Dokainish et al,28 andDavis et al,29 we first assumed g= log()
and fitted the three between-study models described in Section 2.3. Model fit penalising for complexity was compared
using the Deviance Information Criterion (DIC).30 Models with lower values of the DIC are preferred.
As shown in Table 2, differences in DIC across the three correlation structures (Models 1-3) wereminimal. Notably, this
is despite strong evidence of a positive correlation between the 𝜇i1 and μi2 (Model 2 estimate of 𝜌𝜇 = 0.80, 95% credible
interval, Cr-I, 0.24 to 0.99). In the absence of any reduction in DIC from modelling between-study correlations, arguably
the independence model is preferred for this data set.
We then extended the independence model (Model 3) to estimate the best fitting Box-Cox transformation parameter 𝜆,
rather than assuming g= log(). 𝜆was estimated to be 0.23 (95%Cr-I 0.10, 0.34), indicating that the underlying distributions
of test results are slightly less right-skewed than log-logistic (λ = 0). This estimate was not sensitive to the choice of prior.
As shown in Table 2 (Model 4), this model fitted the data marginally better as measured by the mean residual deviance,
but with a minimal reduction in DIC (1.7 points).
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Summary fprs and tprs for each model were calculated by evaluating Equation (1) at the means of the four sets of
random effects, ie, for any threshold C:
logit (fpr (C)) =
m𝜇1 − g (C)
exp (m𝜎1)
logit (tpr (C)) =
m𝜇2 − g (C)
exp (m𝜎2)
.
As shown on Figure 3, these were generally reassuringly similar across models, particularly across the range of thresholds
encompassing most of the data: between thresholds of 100 and 500, the maximum absolute difference in summary tpr
and fpr estimates across models was 1% and 2%, respectively. Model 4 provided substantially lower summary estimates
of the tpr at very high thresholds (>5% absolute difference for thresholds above 780), where the data are very sparse.
Compared with the stratified meta-analyses of data at similar thresholds (Figure 1), the estimates of tpr and fpr are seen
to be coherent (reducing as threshold increases) and more precise.
By drawing predictions for a “new” study population from each set of random effects, and calculating the tpr and fpr
at these predicted values, we also generated 95% prediction intervals.31 For Model 3, Figure 3 shows prediction intervals
in addition to Cr-Is for summary estimates. The very wide prediction intervals, especially for the fpr at lower thresholds,
illustrate that there is a large amount of between-study heterogeneity that is not explained by variation in thresholds.
For comparison, we fitted the model proposed by Steinhauser et al4 to the same data set, using the “diagmeta” R
package.32 A comparison of results with our “Model 3” is provided in the supplementarymaterial. Summary fpr estimates
with 95% CIs were very similar to estimates and Cr-Is from our Model 3. Across thresholds, diagmeta estimated a slightly
higher (up to 3%) summary tpr than our model. See Discussion for possible explanations.
In an additional analysis (Model 5), we explored whether any of the between-study heterogeneity could be explained
by average patient age. Several studies have noted that BNP tends to increase with age.33,34 We fitted an extended version
of Model 3 to assess whether average patient age was associated with the study-level location parameters, 𝜇i1 and 𝜇i2.
Specifically, in Equation (3), we set zi1 = zi2 = (centered) average patient age and zi3 = zi4 = 0. As we built upon Model 3,
all correlation parameters in Equation (3) were also set to zero. Among patients without acute heart failure, the model
estimated that a 5-year increase in average patient age was associated with a 15% increase in mean BNP, but the statistical
evidence for this finding was weak (ratio = 1.15, 95% Cr-I 0.90 to 1.51). As shown on Figure 4, this estimated dependence
of 𝜇i1 on age drives higher estimates of the fpr in older populations. There was no evidence that BNP levels varied with
average patient age among patients with acute heart failure (ratio of means = 1.05, 95% Cr-I 0.90 to 1.22). Unsurprisingly,
given the weak evidence for any association, the model did not lead to any improvement in DIC (Table 2).
Example 2: Spot PCR for diagnosis of preeclampsia
As papers included in this systematic review indicated right skew in values of PCR,35,36 we followed the same analysis
strategy as for Example 1, ie, first, assuming g = log(). As shown in Table 3, again, the DIC did not provide support
for including parameters for between-study correlations. An extension of the independence model to estimate the most
appropriate Box-Cox transformation parameter (Model 4) provided an estimate of 𝜆 = −0.54 (95% Cr-I -0.99, −0.10),
indicating that the underlying distributions of test results are slightly more right skewed than log-logistic. However, this
extension to the model was not supported by the DIC, which increased by 4.1 points relative to Model 3.
Figure 5 shows that the summary estimates from all fourmodels were very similar across the entire range of thresholds.
The maximum absolute difference in tpr was 2% (Model 4 versus 3 at the highest thresholds). Summary fpr estimates
differed by a maximum of 3% across Models 1-3 but up to 5% for Model 4 versus the others. These discrepancies, as seen
FIGURE 3 Summary true positive rate
(tpr) and false positive rate (fpr) estimates
(Models 1-4) for the Brain natriuretic
peptide data across the full range of
thresholds. 95% credible intervals and
prediction intervals shown are from
Model 3 [Colour figure can be viewed at
wileyonlinelibrary.com]
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FIGURE 4 Relationship between
average patient age and false positive rate of
Brain Natriuretic Peptide (Triage assay) in
diagnosing acute heart failure (Model 5
results). Top panel: summary false positive
rate across all thresholds for age 60 and age
80. Bottom panel: summary false positive
rate at a threshold of 100 ng/litre, by
average patient age. Shaded areas are 95%
credible intervals [Colour figure can be
viewed at wileyonlinelibrary.com]
Model Correlation structure Transformation, g() D pD DIC
1 Full correlation matrix log() 143.5 33.7 177.2
2 Structured correlation matrix log() 146.1 34.0 180.1
3 Independence log() 144.9 33.5 178.4
4 Independence Box-Cox with unknown 𝜆 148.1 34.4 182.5
TABLE 3 Comparison of model fit to
the protein to creatinine ratio data,
according to the Deviance Information
Criteria (DIC). D=mean residual
deviance, pD = effective number of
parameters, DIC =D+ pD
on Figure 5, were at the lowest threshold values. In contrast, our summary estimates are markedly different from the best
fittingmodel of Riley et al15 (as shown on Figure 2): mean absolute difference in summary tpr= 4% (maximum 8%), mean
absolute difference in summary fpr = 10% (maximum 22%), compared with our Model 3. Our models suggest a much
greater dependency of tpr and fpr on threshold: for example, across the full range of thresholds, summary fprs from the
model of Riley et al reduced from 0.30 to 0.02, whereas those from our Model 3 reduced from 0.52 to 0.02. This appears
to better capture the range in the observed data.
Prediction intervals are again seen to be extremely wide, reflecting a large amount of between-study heterogeneity in
tpr and fpr even at the same threshold.
See the supplementay material for a comparison of Model 3 results with results from fitting the model proposed by
Steinhauser et al.4 Across thresholds, diagmeta consistently estimated a slightly higher summary tpr than our Model 3
(median difference = 3%). The Steinhauser model estimated a steeper gradient for the dependence of summary fpr on
threshold than ourmodel (maximum absolute difference in fpr= 9%). 95% CIs around summary estimates from diagmeta
were quite different from our 95% Cr-Is, in particular being narrower at lower thresholds and much wider at higher
thresholds for the summary tpr. See Discussion for possible explanations.
5 DISCUSSION
Since the most appropriate threshold at which to operate a test is usually a key clinical question, there is a need to move
beyond “standard” meta-analysis methods1-3 to explicitly quantify how sensitivity and specificity vary across thresholds.
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Perhaps the most obvious approach would be to simply regress logit transformed tprs and fprs (or equivalently, sensitivity
and specificity) on C. However, we see from Equation (1) that this would imply strong assumptions about the underlying
test results: (i) that these have symmetric, logistic distributions; (ii) if assuming constant slope parameters (as is the case
in a standardmeta-regression37) that the scale parameters of these logistic distributions are constant across studies, which
seems unlikely in practice. We have described a model that allows for a range of skewed or symmetric distributions of test
results and estimates study-specific location and scale parameters.
Riley et al15 proposed amultivariate normalmeta-regression approach, in which logit (sensitivity) and logit (specificity)
are modelled as polynomial functions of threshold. For the PCR data set (our Example 2), they found a cubic relationship
with threshold to have the best fit. However, if the common assumption holds that there is a monotonic transformation,
g(), that transforms test results in both the diseased and disease-free populations to logistic, then it follows that logit
(sensitivity) and logit (specificity) are in fact linear functions of g(C).
Other approaches have been suggested, which are based on specific assumptions about the underlying distributions of
test results.4,16 Of these, our proposedmodel is themost similar to that proposed by Steinhauser et al, who assume that test
results have either logistic, log-logistic, normal, or log-normal distributions (depending on the choice of link function, logit
or probit, and the choice of covariate,C or log(C)).4 Ourmodel allows for amore flexible range of underlying distributions
through its ability to estimate a Box-Cox transformation parameter 𝜆 within the model. Alternatively, a value of 𝜆 can be
prespecified based on knowledge of the specific test. We note that although 𝜆 was well estimated in each of our two case
studies, computation time was increased (relative to prespecifying 𝜆 = 0, ie, g() = log()), due to high autocorrelations in
simulated values of this parameter.
An implicit assumption of our model is that the same transformation function, g(), applies to all studies in the
meta-analysis. This seems defensible if all studies assessed the same continuous outcome and that this outcomewasmea-
sured in the same way across all studies. This might not be the case if values are not directly comparable across assays
or machines made by different manufacturers. If this is known to be the case, it might be sensible to perform separate
analyses for each assay or machine (see Example 1, where we restricted the meta-analysis to the 18 studies reporting data
relating to the same assay).
Ourmodel could also be extended to allow 𝜆 to vary randomly across studies (similar to thework of O'Malley and Zou26)
or to estimate a separate transformation parameter for the diseased and disease-free populations. The latter extension
violates the usual assumption made in estimating ROC curves that there is a linear relationship between the tprs and fprs
on the logit scale. However, this assumption could be too restrictive, as noted by Putter et al.14 For our two case study data
sets, neither of these extensions materially impacted on the estimates (not shown).
In addition to increased flexibility in distributional form, our model differs in other ways from that proposed by
Steinhauser et al.4 It is therefore not surprising that we observed some differences in summary estimates and intervals
for both worked examples, even when prespecifying g() = log() (Supplementay material). Firstly, Steinhauser et al made
normal approximations to the true multinomial likelihoods of the count data to apply standard linear mixed modelling
techniques.4 In contrast, we modelled the multinomial likelihoods directly. This automatically accounts for within-study
correlations resulting from a study reporting accuracy measures at more than one threshold and should perform better
at thresholds where the number of positive test results is equal to or close to zero.
Likely the primary driver of the differences in these summary estimates, however, is that our between-study model is
quite different from that of Steinhauser et al.4 We parameterised our model in terms of the means and scale parameters
of transformed test results in the diseased and disease-free populations. We assumed that the means and log-transformed
scale (log(𝜎ij)) parameters are normally distributed across studies. In contrast, Steinhauser et al specified logit (pri1t) and
logit (pri2t) as linear functions of Cit or log (Cit) and assumed that the intercept and slope parameters were normally
distributed across studies.4 Note that, by definition, these slope parameters are equal to−1/𝜎ij (see Equation (1)). As such,
the twomodels make different assumptions about the nature of the between-study variation. As the sets of random effects
in the different models are not linear transformations of each other, the summary estimates and amount of uncertainty
around these may differ (as in the supplementay material). We do not feel that general conclusions on the pattern of
differences between the two models can be made based on only two case studies. However, an argument in favour of
our parameterisation or between-studies model is that it automatically constrains all scale parameters, 𝜎ij, to be positive.
Steinhauser et al noted in their simulation study that occasionally, their parameterisation leads to estimation of impossible
positive slope parameters (equivalently, negative 𝜎ij).4
An alternative would be to extend the “hierarchical summary ROC” parameterisation that is often used for
meta-analysis of diagnostic test accuracy.3 An extension of this to model multiple thresholds9 specifies pri1t and pri2t as
functions of two sets of random effects (study-specific “accuracy” and “shape” parameters) and a number of “threshold”
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FIGURE 5 Summary true positive rate
(tpr) and false positive rate (fpr) estimates
(Models 1-4) for the protein to creatinine
ratio data across the full range of
thresholds. 95% credible intervals and
prediction intervals shown are from
Model 3 [Colour figure can be viewed at
wileyonlinelibrary.com]
parameters, denoted by 𝜃it. The threshold parameters are constrained to be ordered within each study, but are estimated
independently of the 𝜃its in other studies. To extend this model to the case of explicit numerical thresholds, one could
instead specify 𝜃it as a linear function of g(Cit), with the intercepts and natural logarithms of the slope parameters being
two additional sets of random effects.
The parameterisation in this paper may be the most natural for investigating reasons for between-study heterogeneity.
For example, given that BNP levels have been found to increase with patient age within studies,33,34 it was intuitive (in
the absence of individual level data) to fit average patient age as a covariate acting directly on the location parameters,
𝜇ij. In other data sets, we might hypothesise that a covariate is more likely to drive differences in the spread of test scores,
represented by the scale parameters. Heterogeneity in fpr or tpr across studies could be driven by differences in either
of these sets of parameters. Results of analyses with covariates should be interpreted with the caution advised for any
meta-regression, given likely low statistical power, risk of chance findings and, when modelling the effect of average
population characteristics (such as in our worked example), potential ecological bias.37
In our two case studies, we found the majority of summary estimates to be reassuringly similar across variations of our
model. The BNP analyses illustrate that we should be cautious, however, in interpreting estimates at extreme threshold
values with little data. We found no improvement in model fit and very little impact on estimates of target parameters
by estimating between-study correlation parameters relative to estimating each set of random effects separately. This is
probably because there is a very little information to inform the between-study correlations. This will not necessarily be
the case in data sets that include large numbers of studies on large numbers of patients.We also note that our “structured”
correlation matrix is one of many possible structures that might be hypothesised and fitted, depending on knowledge of
the test and data.
Following estimation of “summary” sensitivity and specificity across all thresholds, any one of a number of criteria
might be applied to decide upon the optimal threshold. A very simple approach would be to maximise the Youden Index,
defined as the sensitivity + specificity – 1.38 However, it will not often be appropriate to weight sensitivity and specificity
equally in this way. For example, the potential role of natriuretic peptides in an acute care setting is as a “rule out” test:
in this context, high sensitivity will generally be considered more important than high specificity.22 See Figure 5 of the
work of Steinhauser et al4 for a demonstration of how weighting the Youden index in favour of sensitivity reduces the
“optimal threshold” for BNP testing. One alternative simple approach might be to maximise the sensitivity for a prespec-
ified maximum acceptable fpr. More sophisticated approaches explicitly account for the prevalence of the disease in the
decision population and the costs and anticipated consequences (good and bad) of all four possible outcomes of a test:
true positive, false positive, true negative, false negative. Given an economic decision model, the optimal threshold can
be selected to maximise the expected net benefit.39
We emphasise the importance of utilising multiple pairs of sensitivity and specificity from studies in a meta-analysis,
where available. Even if these are not stated in the text or tables, it will often be possible to extract additional data from
ROC curves using digitized software. These valuable additional data allow for a very flexible modelling approach.
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APPENDIX
PRODUCT NORMAL FORMULATION FOR MULTIVARIATE NORMAL RANDOM EFFECTS
Wepresent a general approach to fitting amultivariate normal distribution of dimensionN in Bayesian statistical software
using MCMC simulation, such as WinBUGS or OpenBUGS. Consider the following multivariate normal distribution:
⎛⎜⎜⎜⎝
𝜃i1
𝜃i2
⋮
𝜃iN
⎞⎟⎟⎟⎠ ∼ Normal
⎛⎜⎜⎜⎝
⎛⎜⎜⎜⎝
𝜇1
𝜇2
⋮
𝜇N
⎞⎟⎟⎟⎠ ,
⎛⎜⎜⎜⎝
V11 V12 · · · V1N
V12 V22 · · · V2N
⋮ ⋮ ⋮ ⋮
V1N V2N · · · VNN
⎞⎟⎟⎟⎠
⎞⎟⎟⎟⎠ .
4802 JONES ET AL.
This can be computed more efficiently by rewriting in the equivalent form
⎛⎜⎜⎜⎝
𝜃i1
𝜃i2
⋮
𝜃iN
⎞⎟⎟⎟⎠ =
⎛⎜⎜⎜⎝
𝜇1
𝜇2
⋮
𝜇N
⎞⎟⎟⎟⎠ +
⎛⎜⎜⎜⎝
𝛿i1
𝛿i2
⋮
𝛿iN
⎞⎟⎟⎟⎠ ,
where ⎛⎜⎜⎜⎝
𝛿i1
𝛿i2
⋮
𝛿iN
⎞⎟⎟⎟⎠ ∼ Normal
⎛⎜⎜⎜⎝
⎛⎜⎜⎜⎝
0
0
⋮
0
⎞⎟⎟⎟⎠ ,
⎛⎜⎜⎜⎝
V11 V12 · · · V1N
V12 V22 · · · V2N
⋮ ⋮ ⋮ ⋮
V1N V2N · · · VNN
⎞⎟⎟⎟⎠
⎞⎟⎟⎟⎠ . (A1)
We could estimate this model by assigning a vague Wishart prior to the precision matrix, but results can be sensitive
to the choice of Wishart parameters.40 It seems preferable instead to give prior distributions directly to interpretable
parameters, such as standard deviation and correlation parameters. This also allows direct comparison of results from
our “full correlation matrix” and “structured correlation matrix” models in the main manuscript or any alternative forms
of the correlation matrix that might be considered appropriate in a given setting.
However, because the multivariate normal distribution is specified in terms of the precision matrix, it is necessary to
invert the covariance matrix at each iteration of the MCMC sampler. Furthermore, at the early stages of the sampler, we
may generate covariance matrices that are near singular, and lead to numerical errors when inverted.
We avoid these problems bywriting themultivariate normal distribution as a sequence of conditional univariate normal
distributions40 and deriving the precision matrix iteratively without requiring a numerical inverse procedure.
Define Σn =
⎛⎜⎜⎜⎝
V11 V12 · · · V1n
V12 V22 · · · V2n
⋮ ⋮ ⋮ ⋮
V1n V2n · · · V𝑛𝑛
⎞⎟⎟⎟⎠ ,n = 1, … ,N such that Σ1 = V11 and the full variance-covariance matrix is equal to
ΣN. Furthermore, Σn can be partitioned as
Σn =
(
Σn−1 v.n
vT.n V𝑛𝑛
)
, where v.n = (V1n V2n · · · Vn − 1,n)T, n = 2,… ,N.
Let us further denoteWn = Σ−1n , n = 1,… ,N.
Say that the 𝛿is are partitioned into two subsets: ΔAi of dimension p and ΔBi of dimension N-p. Then, the multivariate
normal distribution (A1) can be written as a product of two independent multivariate normal distributions of dimensions
p and N-p, respectively: the marginal distribution of ΔAi, which has mean 0 and covariance matrix simply equal to the
relevant partition of ΣN, and the conditional distribution of ΔBi given ΔAi.41
Consider the special case where ΔBi = 𝛿iN, ie, p = N-1. Then, (A1) can be written as a product of
(
𝛿i1
⋮
𝛿iN−1
)
∼ Normal
(( 0
⋮
0
)
,ΣN−1
)
and the following univariate normal distribution for 𝛿iN conditional on 𝛿(i,N − 1) = (𝛿i1, … ,𝛿iN − 1)T:
𝛿iN ∣ 𝛿(i,N−1) ∼ Normal
(
vT
.NWN−1𝛿(i,N−1),VNN − v
T
.NWN−1v.N
)
,
ie, 𝛿iN ∣ 𝛿(i,N−1) ∼ Normal(
∑N−1
i=1
∑N−1
𝑗=1 ViN(WN−1)ij𝛿𝑗,VNN −
∑N−1
i=1
∑N−1
𝑗=1 ViNV𝑗𝑁 (WN−1)ij).
As this formula can be applied iteratively, (A1) can bewritten as a product of conditional univariate normal distributions
as follows:
𝛿1 ∼ Normal (0,V11)
𝛿n ∣ 𝛿1, … , 𝛿n−1 ∼ Normal
(n−1∑
i=1
n−1∑
𝑗=1
Vin(Wn−1)ij𝛿𝑗,Fn−1
)
, n = 2, … ,N,
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where Fn − 1 is the Schur complement of Σn − 1,42 defined as
Fn−1 = Vnn − vT.nWn−1v.n
= Vnn −
n−1∑
i=1
n−1∑
𝑗=1
VinVjn(Wn−1)ij.
Clearly,W1 = 1/V11. For n = 2,… ,N, we can findWn iteratively, as a function ofWn − 1, as follows42(p80):
Wn =
⎛⎜⎜⎝
Wn−1 + 1Fn−1Wn−1v.nv
T
.nWn−1 −
1
Fn−1
Wn−1v.n
− 1Fn−1 (Wn−1v.n)
T 1
Fn−1
⎞⎟⎟⎠ .
Hence, the matrixWn is defined by the elements:
(Wn)nn =
1
Fn−1
(Wn)rn = (Wn)nr = −
1
Fn−1
n−1∑
i=1
(Wn−1)riVin, r = 1, … ,n − 1 (A2)
(Wn)rs = (Wn)sr = (Wn−1)rs +
1
Fn−1
n−1∑
i=1
n−1∑
𝑗=1
(Wn−1)is(Wn−1)rjVinVjn, r = 1, … ,n − 1; s = 1, … ,n − 1. (A3)
From (A2), we see that (A3) is equivalent to
(Wn)rs = (Wn)sr = (Wn−1)rs + Fn−1(Wn)rn(Wn)sn.
